Immunogenic properties of chimeric potato virus X particles displaying the hepatitis C virus hypervariable region I peptide R9

Journal of Virological Methods

Volumn 166, Issue 1-2, 2010, Pages 12-20

  Uhde Holzem, Kerstin ^a   Schlösser, Verena ^a   Viazov, Sergei ^b   Fischer, Rainer ^a,c   Commandeur, Ulrich ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

Author keywords

Chimeric virus particle; Epitope presentation; Hepatitis C virus; Plant based vaccine; Potato virus X; Recombinant protein

Indexed keywords

COAT PROTEIN; PEPTIDE ANTIBODY; PEPTIDE DERIVATIVE; PEPTIDE R9; UNCLASSIFIED DRUG;

ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; CHIMERA; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE CONSTRUCT; GENE EXPRESSION; GENE SEQUENCE; GENETIC ENGINEERING; GENETIC VARIABILITY; HEPATITIS C VIRUS; IMMUNIZATION; IMMUNOGENICITY; NICOTIANA BENTHAMIANA; NONHUMAN; PEPTIDE ANALYSIS; PLANT LEAF; POTEXVIRUS; PRIORITY JOURNAL; PROTEIN ISOLATION; PROTEIN PURIFICATION; VACCINE PRODUCTION; VIRUS PARTICLE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; COMPLEMENTARITY DETERMINING REGIONS; FEMALE; GENETIC VECTORS; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON; POTEXVIRUS; RECOMBINATION, GENETIC; TOBACCO; VIRAL ENVELOPE PROTEINS; VIRAL HEPATITIS VACCINES; VIRION;

HEPATITIS C VIRUS; MUS; NICOTIANA BENTHAMIANA; POTATO VIRUS X;

EID: 77952669353     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2010.01.017     Document Type: Article

References (63)

1. Baratova L.A., Grebenshchikov N.I., Shishkov A.V., Kashirin I.A., Radavsky J.L., Jarvekulg L., Saarma M. The topography of the surface of potato virus X: tritium planigraphy and immunological analysis. J. Gen. Virol. 1992, 73(Pt 2):229-235.
2. Barnard D.L. Pegasys (Hoffmann-La Roche). Curr. Opin. Invest. Drugs 2001, 2:1530-1538.
3. Baulcombe D., Chapman S., Santa Cruz S. Jellyfish green fluorescent protein as a reporter for virus infections. Plant J. 1995, 7:1045-1053.
4. Bendahmane M., Koo M., Karrer E., Beachy R.N. Display of epitopes on the surface of tobacco mosaic virus: impact of charge and isoelectric point of the epitope on virus-host interactions. J. Mol. Biol. 1999, 290:9-20.
5. Block T.M., Mehta A.S., Fimmel C.J., Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003, 22:5093-5107.
6. Bowen D.G., Walker C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005, 436:946-952.
7. Cerino A., Meola A., Segagni L., Furione M., Marciano S., Triyatni M., Liang T.J., Nicosia A., Mondelli M.U. Monoclonal antibodies with broad specificity for hepatitis C virus hypervariable region 1 variants can recognize viral particles. J. Immunol. 2001, 167:3878-3886.
8. Craxi A., Laffi G., Zignego A.L. Hepatitis C virus (HCV) infection: a systemic disease. Mol. Aspects Med. 2008, 29:85-95.
9. Cruz S.S., Chapman S., Roberts A.G., Roberts I.M., Prior D.A., Oparka K.J. Assembly and movement of a plant virus carrying a green fluorescent protein overcoat. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:6286-6290.
10. Donnelly M.L., Hughes L.E., Luke G., Mendoza H., ten Dam E., Gani D., Ryan M.D. The 'cleavage' activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring '2A-like' sequences. J. Gen. Virol. 2001, 82:1027-1041.
11. Donnelly M.L., Luke G., Mehrotra A., Li X., Hughes L.E., Gani D., Ryan M.D. Analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal 'skip'. J. Gen. Virol. 2001, 82:1013-1025.
12. Farci P., Shimoda A., Wong D., Cabezon T., De Gioannis D., Strazzera A., Shimizu Y., Shapiro M., Alter H.J., Purcell R.H. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:15394-15399.
13. Frasca L., Scotta C., Del Porto P., Nicosia A., Pasquazzi C., Versace I., Masci A.M., Racioppi L., Piccolella E. Antibody-selected mimics of hepatitis C virus hypervariable region 1 activate both primary and memory Th lymphocytes. Hepatology 2003, 38:653-663.
14. Halpin C., Cooke S.E., Barakate A., El Amrani A., Ryan M.D. Self-processing 2A-polyproteins-a system for co-ordinate expression of multiple proteins in transgenic plants. Plant J. 1999, 17:453-459.
15. Hayashi J., Aoki H., Arakawa Y., Hino O. Hepatitis C virus and hepatocarcinogenesis. Intervirology 1999, 42:205-210.
16. Heintges T., Erhardt A., Sagir A., Häussinger D. Kombinationstherapie der chronischen Hepatitis C. Dtsch. Ärzteblatt. 2002, 99:A1239-A1241.
17. Koenig R. Anomalous behavior of the coat proteins of potato virus X and cactus virus X during electrophoresis in dodecyl sulfate-containing polyacrylamide gels. Virology 1972, 50:263-266.
18. Koenig R., Stegemann H., Francksen H., Paul H.L. Protein subunits in the potato virus X group. Determination of the molecular weights by polyacrylamide electrophoresis. Biochim. Biophys. Acta 1970, 207:184-189.
19. Koenig R., Torrance L. Antigenic analysis of potato virus X by means of monoclonal antibodies. J. Gen. Virol. 1986, 67:2145-2151.
20. Koenig R., Tremaine J.H., Shepard J.F. In situ degradation of the protein chain of potato virus X at the N- and C-termini. J. Gen. Virol. 1978, 38:329-337.
21. Lacomme C., Smolenska L., Wilson T.M.A. Genetic engineering and the expression of foreign peptides or proteins with plant virus-based vectors. Genetic Engineering: Principles and Methods 1998, vol. 20:225-237. Plenum Press, New York.
22. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
23. Lico C., Capuano F., Renzone G., Donini M., Marusic C., Scaloni A., Benvenuto E., Baschieri S. Peptide display on potato virus X: molecular features of the coat protein-fused peptide affecting cell-to-cell and phloem movement of chimeric virus particles. J. Gen. Virol. 2006, 87:3103-3112.
24. Ma J.K., Drake P.M., Christou P. The production of recombinant pharmaceutical proteins in plants. Nat. Rev. Genet. 2003, 4:794-805.
25. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
26. Marconi G., Albertini E., Barone P., De Marchis F., Lico C., Marusic C., Rutili D., Veronesi F., Porceddu A. In planta production of two peptides of the Classical Swine Fever Virus (CSFV) E2 glycoprotein fused to the coat protein of potato virus X. BMC Biotechnol. 2006, 6:29.
27. Marusic C., Rizza P., Lattanzi L., Mancini C., Spada M., Belardelli F., Benvenuto E., Capone I. Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. J. Virol. 2001, 75:8434-8439.
28. McHutchison J.G., Fried M.W. Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin. Liver Dis. 2003, 7:149-161.
29. Mihailova M., Fiedler M., Boos M., Petrovskis I., Sominskaya I., Roggendorf M., Viazov S., Pumpens P. Preparation of hepatitis C virus structural and non-structural protein fragments and studies of their immunogenicity. Protein Expr. Purif. 2006, 50:43-48.
30. Mondelli M.U., Cerino A., Meola A., Nicosia A. Variability or conservation of hepatitis C virus hypervariable region 1? Implications for immune responses. J. Biosci. 2003, 28:287-304.
31. Natilla A., Piazzolla G., Nuzzaci M., Saldarelli P., Tortorella C., Antonaci S., Piazzolla P. Cucumber mosaic virus as carrier of a hepatitis C virus-derived epitope. Arch. Virol. 2004, 149:137-154.
32. Nemchinov L.G., Liang T.J., Rifaat M.M., Mazyad H.M., Hadidi A., Keith J.M. Development of a plant-derived subunit vaccine candidate against hepatitis C virus. Arch. Virol. 2000, 145:2557-2573.
33. Neumann-Haefelin C., Blum H.E., Chisari F.V., Thimme R. T cell response in hepatitis C virus infection. J. Clin. Virol. 2005, 32:75-85.
34. Nuzzaci M., Piazzolla G., Vitti A., Lapelosa M., Tortorella C., Stella I., Natilla A., Antonaci S., Piazzolla P. Cucumber mosaic virus as a presentation system for a double hepatitis C virus-derived epitope. Arch. Virol. 2007, 152:915-928.
35. O'Brien G.J., Bryant C.J., Voogd C., Greenberg H.B., Gardner R.C., Bellamy A.R. Rotavirus VP6 expressed by PVX vectors in Nicotiana benthamiana coats PVX rods and also assembles into virus like particles. Virology 2000, 270:444-453.
36. Okuda M., Hino K., Korenaga M., Yamaguchi Y., Katoh Y., Okita K. Differences in hypervariable region 1 quasispecies of hepatitis C virus in human serum, peripheral blood mononuclear cells, and liver. Hepatology 1999, 29:217-222.
37. Piazzolla G., Nuzzaci M., Tortorella C., Panella E., Natilla A., Boscia D., De Stradis A., Piazzolla P., Antonaci S. Immunogenic properties of a chimeric plant virus expressing a hepatitis C virus (HCV)-derived epitope: new prospects for an HCV vaccine. J. Clin. Immunol. 2005, 25:142-152.
38. Porta C., Spall V.E., Findlay K.C., Gergerich R.C., Farrance C.E., Lomonossoff G.P. Cowpea mosaic virus-based chimaeras. Effects of inserted peptides on the phenotype, host range, and transmissibility of the modified viruses. Virology 2003, 310:50-63.
39. Puntoriero G., Meola A., Lahm A., Zucchelli S., Ercole B.B., Tafi R., Pezzanera M., Mondelli M.U., Cortese R., Tramontano A., Galfre G., Nicosia A. Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants. EMBO J. 1998, 17:3521-3533.
40. Rajender Reddy K., Modi M.W., Pedder S. Use of peginterferon alfa-2a (40kDa) (Pegasys) for the treatment of hepatitis C. Adv. Drug Deliv. Rev. 2002, 54:571-586.
41. Rehermann B., Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 2005, 5:215-229.
42. Roccasecca R., Folgori A., Ercole B.B., Puntoriero G., Lahm A., Zucchelli S., Tafi R., Pezzanera M., Galfre G., Tramontano A., Mondelli M.U., Pessi A., Nicosia A., Cortese R., Meola A. Induction of cross-reactive humoral immune response by immunization with mimotopes of the hypervariable region 1 of the hepatitis C virus. Int. Rev. Immunol. 2001, 20:289-300.
43. Roccasecca R., Folgori A., Ercole B.B., Puntoriero G., Lahm A., Zucchelli S., Tafi R., Pezzanera M., Galfre G., Tramontano A., Mondelli M.U., Pessi A., Nicosia A., Cortese R., Meola A. Mimotopes of the hyper variable region 1 of the hepatitis C virus induce cross-reactive antibodies directed against discontinuous epitopes. Mol. Immunol. 2001, 38:485-492.
44. Rollier C., Depla E., Drexhage J.A., Verschoor E.J., Verstrepen B.E., Fatmi A., Brinster C., Fournillier A., Whelan J.A., Whelan M., Jacobs D., Maertens G., Inchauspe G., Heeney J.L. Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. J. Virol. 2004, 78:187-196.
45. Ross R.S., Viazov S., Renzing-Kohler K., Roggendorf M. Changes in the epidemiology of hepatitis C infection in Germany: shift in the predominance of hepatitis C subtypes. J. Med. Virol. 2000, 60:122-125.
46. Ryan M.D., Drew J. Foot-and-mouth disease virus 2A oligopeptide mediated cleavage of an artificial polyprotein. EMBO J. 1994, 13:928-933.
47. Ryan M.D., King A.M., Thomas G.P. Cleavage of foot-and-mouth disease virus polyprotein is mediated by residues located within a 19 amino acid sequence. J. Gen. Virol. 1991, 72:2727-2732.
48. Shang D., Zhai W., Allain J.P. Broadly cross-reactive, high-affinity antibody to hypervariable region 1 of the hepatitis C virus in rabbits. Virology 1999, 258:396-405.
49. Simmonds P., Bukh J., Combet C., Deleage G., Enomoto N., Feinstone S., Halfon P., Inchauspe G., Kuiken C., Maertens G., Mizokami M., Murphy D.G., Okamoto H., Pawlotsky J.M., Penin F., Sablon E., Shin I.T., Stuyver L.J., Thiel H.J., Viazov S., Weiner A.J., Widell A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005, 42:962-973.
50. Smolenska L., Roberts I.M., Learmonth D., Porter A.J., Harris W.J., Wilson T.M., Santa Cruz S. Production of a functional single chain antibody attached to the surface of a plant virus. FEBS Lett. 1998, 441:379-382.
51. Torresi J., Bharadwaj M., Jackson D.C., Gowans E.J. Neutralising antibody, CTL and dendritic cell responses to hepatitis C virus: a preventative vaccine strategy. Curr. Drug Targets 2004, 5:41-56.
52. Twyman R.M., Schillberg S., Fischer R. Transgenic plants in the biopharmaceutical market. Expert Opin. Emerg. Drugs 2005, 10:185-218.
53. Uhde-Holzem K., Fischer R., Commandeur U. Genetic stability of recombinant potato virus X virus vectors presenting foreign epitopes. Arch. Virol. 2006.
54. Uhde K., Fischer R., Commandeur U. Expression of multiple foreign epitopes presented as synthetic antigens on the surface of potato virus X particles. Arch. Virol. 2005, 150:327-340.
55. von Hahn T., Yoon J.C., Alter H., Rice C.M., Rehermann B., Balfe P., McKeating J.A. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007, 132:667-678.
56. Warrens A.N., Jones M.D., Lechler R.I. Splicing by overlap extension by PCR using asymmetric amplification: an improved technique for the generation of hybrid proteins of immunological interest. Gene 1997, 186:29-35.
57. Wasley A., Alter M.J. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin. Liver Dis. 2000, 20:1-16.
58. Weiner A.J., Brauer M.J., Rosenblatt J., Richman K.H., Tung J., Crawford K., Bonino F., Saracco G., Choo Q.L., Houghton M., et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 1991, 180:842-848.
59. Werner S., Marillonnet S., Hause G., Klimyuk V., Gleba Y. Immunoabsorbent nanoparticles based on a tobamovirus displaying protein A. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:17678-17683.
60. Yusibov V., Rabindran S., Commandeur U., Twyman R.M., Fischer R. The potential of plant virus vectors for vaccine production. Drugs R D 2006, 7:203-217.
61. Zeisel M.B., Fafi-Kremer S., Fofana I., Barth H., Stoll-Keller F., Doffoel M., Baumert T.F. Neutralizing antibodies in hepatitis C virus infection. World J. Gastroenterol. 2007, 13:4824-4830.
62. Zibert A., Meisel H., Kraas W., Schulz A., Jung G., Roggendorf M. Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus. Hepatology 1997, 25:1245-1249.
63. Zucchelli S., Roccasecca R., Meola A., Ercole B.B., Tafi R., Dubuisson J., Galfre G., Cortese R., Nicosia A. Mimotopes of the hepatitis C virus hypervariable region 1, but not the natural sequences, induce cross-reactive antibody response by genetic immunization. Hepatology 2001, 33:692-703.